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Outcome of bioprosthetic valve replacement in dogs with tricuspid valve 1 
dysplasia 2 
 3 
Objectives: to describe the short term and long term outcome in dogs with tricuspid 4 
valve dysplasia (TVD) undergoing tricuspid valve replacement under 5 
cardiopulmonary bypass (CPB). 6 
Methods: data were collected from the hospital records of all dogs that had 7 
undergone tricuspid valve replacement under cardiopulmonary bypass between 2006-8 
2012. Dogs were considered candidates for TV replacement if they had severe 9 
tricuspid valve regurgitation associated with clinical signs of cardiac compromise.  10 
Results: 9 dogs of 6 different breeds were presented. Median age was 13 months 11 
(range 7-61 months), median weight 26.5kg (range 9.7-59 kg). Eight bovine 12 
pericardial valves and 1 porcine aortic valve designed for use in the mitral position in 13 
man were used. One non-fatal intra-operative complication occurred. Complications 14 
during hospitalisation occurred in 6 dogs, 4 of which were fatal. Of the 5 dogs 15 
discharged, one presented dead due to haemothorax after minor trauma 7 days later. 16 
The 4 remaining dogs survived a median of 533 days; all of these dogs received a 17 
bovine pericardial valve. 18 
Clinical significance: based on our results, TVR with bovine or porcine prosthetic 19 
valves is associated with a high incidence of complications. Until better techniques 20 
are devised for controlling the canine coagulation system or less thrombogenic valve 21 
materials are developed, bioprosthetic valve replacement using this protocol remains a 22 
high risk treatment in dogs. 23 
  24 
Introduction  25 
Tricuspid valve dysplasia is an uncommon congenital malformation in small animals, 26 
accounting for approximately 3% of congenital cardiac malformations in dogs 27 
(Oliveira et al. 2011). It is more common in larger dogs, with Labrador Retrievers, 28 
English Bulldogs and Golden Retrievers amongst others predisposed (Famula et al. 29 
2005, Oliveira et al. 2011). A spectrum of valvular lesions are possible with the most 30 
common being thickened, immobile septal leaflets that are effectively tethered to the 31 
ventricular septum (Liu & Tilley 1976). The resulting valvular dysfunction leads to 32 
progressive right atrial and ventricular volume overload, with chamber dilatation and 33 
dilatation of the tricuspid annulus, which further exacerbates the valvular 34 
incompetence. Treatment options for canine tricuspid valve dysplasia typically consist 35 
of medical therapy for right sided heart failure (Adin 2008). In the human literature 36 
both valve repair and valve replacement are reported with the decision based on the 37 
specific valvular morphology and whether repair is feasible.  In man, both techniques 38 
have advantages and disadvantages.  There is one report describing the surgical 39 
treatment of tricuspid valve dysplasia in the veterinary literature to date (Arai et al. 40 
2011) which documents the outcome of bioprosthetic valve implantation, under 41 
conditions of cardiopulmonary bypass (CPB) in 12 dogs. In that study, dogs were 42 
considered candidates for tricuspid valve replacement if they had severe tricuspid 43 
valve regurgitation associated with clinical signs of cardiac compromise such as 44 
severe exercise intolerance and ascites, and required on-going medical therapy (Arai 45 
et al).  Ten of the dogs survived surgery with a further two euthanatised at 10 and 13 46 
months post-operatively due to inflammatory pannus formation and consequent 47 
failure of the bioprosthesis. The purpose of the study reported here is to describe the 48 
short and long term outcomes in a further cohort of dogs. 49 
 50 
Materials and Methods 51 
 Similar to Arai et al.’s description (2011), tricuspid valve replacement was undertaken in 52 
dogs that had severe tricuspid valve incompetence associated with right heart failure and 53 
whose owners fully accepted the risks associated with this treatment, along with the 54 
financial obligations associated with surgery. Written client consent was obtained from all 55 
owners. Data were collected from the medical records of all dogs that had undergone 56 
tricuspid valve replacement under CPB at the RVC between 2006 and 2012.  Data gathered 57 
included: signalment, clinical signs, previous and current medication, echocardiographic 58 
findings, duration of anaesthesia, CPB and cross clamp time, type and size of valve used, 59 
pre- and post-operative complications and time to discharge. Follow up data were obtained 60 
from the medical records for subsequent visits to our referral centre, and long term 61 
outcome was obtained from either the medical record if the patient was known to be 62 
deceased, including post mortem data if applicable, or by referring veterinarian or owner 63 
contact. Minor complications were defined as those requiring no surgical intervention; 64 
major complications were those requiring surgical intervention or resulting in death.  65 
The technique for tricuspid valve replacement has been previously reported by Arai 66 
and others (Arai et al. 2011). The protocols for anaesthesia and cardiopulmonary 67 
bypass used in this study, have also been reported previously (Griffiths et al. 2005, 68 
Orton et al. 2001).  All dogs were administered peri-operative antibiotics (cefuroxime 69 
(Zinacef; GlaxoSmithKline) n=8, imipenem (Primaxin; Merck Sharp & Dohme Ltd),  70 
n=1). Briefly, a right fifth intercostal thoracotomy was performed. The pericardium 71 
was opened and pericardial basket sutures placed. Venous drainage was achieved 72 
through two right angle cannulas placed in the cranial and caudal vena cavae through 73 
purse-string sutures in the adjacent right atrial myocardium.  The arterial limb of the 74 
circuit was completed with arterial cannula in the right external carotid. 75 
Cardiopulmonary bypass was initiated and the dogs were cooled to an oesophageal 76 
temperature of 28º C.  Rummel tourniquets of umbilical tape were used to form a seal 77 
around the intracaval part of the venous cannulas and the azygous rummel was 78 
tightened to stop flow through the azygous vein.  An 18g cardioplegia cannula was 79 
inserted into the aortic root through a horizontal mattress suture of 5-0 polypropylene 80 
(Prolene; Ehicon) with expanded polytetrofluoroethylene (ePTFE) pledgets.  81 
Following aortic cross-clamping, cold (4º C) cardioplegia solution (Cardioplegia 82 
infusion; Martindale), combined with blood from the bypass circuit, was infused into 83 
the aortic root.  Cardioplegia was delivered at 20 minute intervals or whenever 84 
mechanical cardiac muscular activity was observed.   85 
The right atrial incision was made along a line parallel with the atrioventricular 86 
groove and equidistant from it and the dorsal pericardial reflection of the right atrium.  87 
Stay sutures of 3-0 polyglactin 910 (Vicryl; Ethicon) were placed around the atrial 88 
incision to maintain exposure of the tricuspid valve orifice.  The tricuspid valve was 89 
inspected and the septal leaflet excised.  Interrupted mattress sutures of 2-0 braided 90 
polyester with 7mm x 3mm PTFE pledgets (Ti-Cron Davis and Geck) were placed 91 
around the tricuspid annulus such that the edges of the pledgets were closely 92 
approximated on the ventricular side of the annulus, (Figure 1).  The mural valve 93 
leaflet was “gathered” or “reefed” to preserve chordal attatchments but prevent the 94 
valve leaflet impinging on the artificial valve.  Once all the sutures had been placed 95 
around the annulus, a valve “sizer” was gently inserted into the annulus so that the 96 
correct valve size could be selected.  The pre-placed sutures were then passed through 97 
the suturing ring of the correctly sized artificial valve at even space intervals, and tied, 98 
(Figure 2).  The valve holding apparatus was removed, the heart was de-aired by 99 
allowing it to fill with blood from the azygous vein.  The atriotomy incision was 100 
closed using 4-0 polypropylene (Prolene; Ethicon) with ePTFE pledgets in a 101 
continuous mattress suture oversewn by a simple continuous suture.  Two suture 102 
strands were used, one starting from each end of the atriotomy and the sutures were 103 
tied in the middle of the incision following a final de-airing of the atrium.   104 
During atriotomy closure the dogs were warmed to an oesophageal temperature of 105 
370C.  At the end of atriotomy closure, the aortic cross clamp was removed and the 106 
myocardium allowed to re-perfuse.  If normal sinus rhythm did not resume, 107 
ventricular fibrilliation was managed by direct internal electrical defibrillation (20 – 108 
50J) and asystole was managed by the placement of temporary epicardial pacing leads 109 
(Ethicon temporary pacing leads (2-0)), and pacing begun at 100 beats per minute.  110 
The dogs were weaned from bypass, a thoracostomy tube was placed and the 111 
thoracotomy closed in a routine fashion.  Ventilatory support was provided using a 112 
mechanical ventilator that provided inspiratory pressure support (2 to 8 cm H2O) 113 
along with supplemental oxygen.  The level of ventilatory support and supplemental 114 
oxygen required was determined by results of arterial blood gas analysis. The dogs 115 
were recovered from anaesthesia in the intensive care unit where their therapy was 116 
adjusted according to perceived needs based on changes in arterial blood gas 117 
measurements,  blood pressure, urine production and fluid retrieved from the chest 118 
drain.  Once the thoracostomy tube had been removed and all post-operative bleeding 119 
had stopped, heparin (100 U kg-1 SC q 8h) was administered in all but one dog (which 120 
received aspirin alone).  Warfarin (0.1 mg kg-1 PO q 24hrs), was initiated the day after 121 
heparin was started and was continued for three months after valve implantation.  122 
Heparin therapy was discontinued three days after initiation of warfarin treatment at 123 
which stage aspirin was started and continued for the remainder of the dogs life. The 124 
dose of warfarin was adjusted according to changes in the measured prothrombin time 125 
and subsequent calculation of the international normalized ratio (INR) with the goal 126 
of maintaining the INR between 2.5 and 3.5. The INR was calculated 72 hours after 127 
initiating warfarin and checked weekly to 4-6 weeks depending on the result of the 128 
INR at each check.  129 
Dogs remained in the ICU for a minimum of five days. Unless complications were 130 
encountered, echocardiography was repeated at 48 hours post-operatively and on 131 
alternate days thereafter for the remainder of their hospitalisation.  132 
 133 
Results  134 
Nine dogs met the inclusion criteria with their owners electing surgery. A variety of 135 
breeds were represented, with Labrador Retrievers (n=3) being the most common, 136 
followed by Golden Retrievers (n=2) and one each of Dogue de Bordeaux, Rhodesian 137 
Ridgeback, Rottweiler and Bassett Hound, (Table 1).  138 
 Six males, (two neutered) and three females, (all entire) were treated. Median age at 139 
surgery was 13 months (range 7-61 months). Median weight was 26.5kg (range 9.7-140 
59 kg), (Table 1). Six dogs had a history of CHF prior to surgery and three had atrial 141 
fibrillation. In one dog, electrical cardioconversion was attempted prior to surgery but 142 
was unsuccessful. A variety of clinical signs were present including exercise 143 
intolerance, polyuria/polydipsia, distended abdomen, lethargy, stunted growth, 144 
dyspnoea and cachexia. All dogs apart from one were receiving a combination of 145 
medications prior to surgery; furosemide (Frusedale; Dechra, Frusemid; Millpledge, 146 
Frusol; Rosemont),  (n=6), pimobendan (Vetmedin; Boehringer Ingelheim), (n=3), 147 
enalapril (Enacard; Merial), (n=8), digoxin (Lanoxin; Asper Pharma trading), (n=3), 148 
spironolactone (Prilactone; Ceva), (n=1).  149 
The grade of heart murmur was recorded in 6 dogs pre-operatively, and was a grade 150 
V/VI in five and III/VI in one. On echocardiographic examination no dogs had 151 
evidence of apical valve displacement and all dogs had tethering of the septal valve 152 
leaflet to the septal wall. The free wall leaflets varied in appearance, ranging from thin 153 
and tethered to very thick, with variable chordae tendinae attachments. Eight dogs had 154 
tricuspid regurgitation, and the remaining dog had tricuspid stenosis. 155 
Cross clamp and total bypass times were available in 8 dogs with a median of 65 156 
minutes (range 45-90) and 98.5 minutes (range 65-120) respectively. One dog had a 157 
patent foramen ovale closed during the procedure. Eight bovine pericardial valves 158 
were used (27-33mm sizes), (Perimount Plus; Carpentier-Edwards) and one 25 mm 159 
porcine aortic valve prosthesis (Baxter).  160 
One intra-operative complication occurred: a tear in the aorta at the insertion site of 161 
the cardioplegia cannula which was successfully repaired with sutures. All dogs 162 
survived surgery but six dogs experienced complications during hospitalisation, and 163 
four of these were fatal. Of the minor complications, one dog developed partial 164 
tongue necrosis, minor wound dehiscence and a supraventricular tachycardia, all of 165 
which resolved. The other dog developed a pneumothorax after thoracostomy tube 166 
removal which was successfully managed by a period of continuous pleural drainage. 167 
This dog also developed a large right atrial thrombus but remained stable with a good 168 
cardiac output and was discharged 29 days post-operatively. Of the dogs experiencing 169 
fatal complications, one dog developed acute central nervous system (CNS) signs on 170 
the morning of planned hospital discharge (day five post-operatively). He 171 
subsequently became acutely hypotensive with low output heart failure after an 172 
uneventful initial recovery, presumed to be due to a thrombus on the valve. The cause 173 
of the neurological signs was thought likely due to a transient hypoxia either due to 174 
low output heart failure or a pulmonary embolus. This dog was treated with a 175 
thrombolytic agent (Tenecteplase (TNKase®; Genentech)) at a dose according to the 176 
recommendations in people, but developed profuse haemorrhagic diarrhoea and was 177 
euthanatised.  Post mortem evaluation confirmed the presence of thrombus on this 178 
dog’s valve as a cause of acute valve failure (Figure 3). This dog was the only case 179 
that had a porcine aortic valve implanted, and was also the only dog to receive just 180 
aspirin rather than heparin and warfarin as well.   The second dog developed 181 
hypotension, hypoxia and oliguria approximately 12 hours post-operatively. Despite 182 
aggressive supportive care this dog continued to deteriorate and was euthanatised at 183 
approximately 20 hours post-operatively.  The third dog initially recovered well but 184 
remained in the hospital while warfarin treatment was stabilised.  He became pyrexic 185 
on the 8th post-operative day and on day 11, a positive blood culture confirmed 186 
highly resistant strains of Enterobacter cloacae and Escherichia coli. This dog 187 
experienced a suspected brain stem haemorrhage, with the loss of brain stem auditory 188 
evoked responses on day 14 and was euthanatised. The fourth dog also made a good 189 
recovery initially but became pyrexic on the fourth post-operative day and died from a 190 
cardiorespiratory arrest.  Again, a multi-resistant Enterobacter cloacae and 191 
Acinetobacter baumanii were cultured from ante mortem blood samples.  192 
Five dogs were discharged from the hospital. One dog collapsed after a minor fall at 193 
home and was returned to the hospital seven days after discharge, and was dead on 194 
arrival. At post mortem examination this dog had a large volume intrathoracic 195 
haemorrhage, likely due to minor trauma in conjunction with the anti-coagulant 196 
medications. Despite this fatal haemorrhage, this dog had thrombus covering his 197 
valve, (Figure 3). Of the four remaining dogs, one dog had a low volume pleural 198 
effusion at three months post-operatively at which stage he was started on furosemide. 199 
He remained well for the following month, and at 4 months post-operatively he had 200 
no evidence of a thrombus or micro clots, and had only mild tricuspid regurgitation.  201 
At 8 months post-operatively he was presented in congestive heart failure and atrial 202 
fibrillation; a very large thrombus was found on the valve causing valvular stenosis 203 
and the dog was euthanatised. The second dog had an echocardiogram performed four 204 
months post-operatively, which showed improved right ventricular function and a 205 
reduction in his heart murmur from a grade IV/VI to a grade I/VI, but was 206 
euthanatised due to metastatic osteosarcoma at 246 days after surgery. Revision 207 
surgery was attempted in the third dog 12 months post-operatively, but she was 208 
euthanatised on the table when it became clear that explanting the valve would be 209 
impossible due to extensive inflammatory tissue engulfing the prosthesis. 210 
Inflammatory pannus was confirmed histologically at post mortem examination 211 
(Figure 4).  The final dog collapsed and died 1277 days post-operatively whilst 212 
exercising. A post mortem examination was declined but three months prior to this a 213 
repeat echocardiogram of the valve showed no abnormalities, (Table 1).  214 
Discussion  215 
In the group of dogs undergoing cardiopulmonary bypass for tricuspid valve 216 
replacement in the study reported here, only 5/9 dogs survived to discharge. Of the 217 
five dogs that died in the short term, three died because of problems associated with 218 
coagulation (thrombus formation, n=1), or anticoagulation (fatal hemorrhage, n=2). 219 
Two dogs developed pyrexia with positive blood cultures, and it is assumed they were 220 
septicaemic, several days after apparently uneventful recovery. Of the four dogs that 221 
survived in the long term, two died as a result of stenosis of the valve with the 222 
presence of fibrous tissue (inflammatory pannus/organized thrombus) confirmed 223 
histopathologically, the cause of one death was unknown and one death (euthanasia 224 
because of osteosarcoma) was unrelated to cardiac disease.  225 
There is only one other report in the veterinary literature describing tricuspid valve 226 
replacement in dogs (Arai et al. 2011).  The mortality rate in the study reported here 227 
was higher in the short term (n=5/9) when compared to Arai et al. 2011 (n=2/12). The 228 
reason for this difference is unknown; the surgical technique including cannulation 229 
methods are identical between both centers, indeed, the surgery, perfusion and post 230 
operative care team from Colorado State University performed the first tricuspid 231 
valve replacement at the Royal Veterinary College (RVC), alongside the RVC team.  232 
These nine dogs, along with 12 dogs that underwent open patch grafting of the right 233 
ventricular outflow tract to treat pulmonic stenosis and double chambered right 234 
ventricle (unpublished data), represent the first 21 dogs operated on at the RVC under 235 
cardiopulmonary bypass and so it would be reasonable to expect a higher incidence of 236 
technical failures initially, but similarly, it would be expected that these would reduce 237 
as familiarity with the techniques developed. 238 
Most of the deaths in the dogs in our study were related to problems with blood 239 
clotting (inadequate haemostasis and thrombogenic complications), despite our 240 
attempts to use the anti-coagulation therapy previously reported, which consisted of  241 
heparin and warfarin once post-operative bleeding had ceased.  The only difference 242 
between the protocol used in the study reported here and that reported by Arai et al. 243 
(2011), was that warfarin therapy was started the day following heparin initiation in 244 
our population, compared with the second post-operative day in the study reported by 245 
Arai et al. (2011).  One of the dogs in our study only received antiplatelet therapy 246 
(aspirin) following immediate post-operative heparin therapy, based on the 247 
recommendation of an experienced human cardiac surgeon; and this was the dog that 248 
died as a result of acute valve failure secondary to thrombus formation. Although only 249 
one case, it would appear that aspirin alone is not an effective strategy in dogs, despite 250 
its success in humans. This was also the only dog in our paper to have a porcine aortic 251 
valve implanted. One of Arai et al.’s (2011) conclusions was that inflammatory 252 
pannus was more likely with implantation of a bovine pericardial valve (2/4 253 
developed this in their cases), as opposed to a porcine aortic valve (0/5 developed 254 
this), however because the only case that received a porcine valve was also the only 255 
case treated with aspirin alone, the finding of tricuspid valve thrombus on post 256 
mortem should be interpreted cautiously. In contrast with our findings, humans appear 257 
to have a relatively low risk of death or embolic complications in the first three 258 
months following surgery for aortic valve bioprosthesis replacement (Brennan et al. 259 
2012).  This study showed that the combination of aspirin and warfarin relative to 260 
aspirin alone had a lower adjusted risk of death and embolic events, however this 261 
group of patients had a higher risk of bleeding (Brennan et al. 2012). A meta-analysis 262 
from 2001 on humans with prosthetic heart valves, concluded that adding low dose 263 
aspirin to warfarin decreases the risk of embolism or death, with a slightly increased 264 
risk of bleeding, and concluded that there was a favorable risk to benefit ratio with 265 
this protocol (Massel & Little 2001). Even in human medicine, controlling the balance 266 
of the coagulation cascade post-operatively is clearly still a challenge, however, on 267 
the evidence of the dogs reported here, much work is needed before we can 268 
recommend the use of valves that require even short-term anticoagulation in dogs.  269 
The reason tissue valves were chosen as the prosthesis for these dogs was because 270 
human patients with tissue valves do not require life-long anticoagulant therapy once 271 
the exposed elements of the valve are coated with native endothelium, (Bloomfield 272 
2002). In addition, Orton et al. (2005) concluded that long term anticoagulant therapy 273 
was difficult to monitor and control in a report of a series of dogs that underwent 274 
mitral valve replacement using a bi-leaflet mechanical valve; with thrombus-related 275 
valve failure seen as a frequent event (Orton et al. 2005).  Again, it is not clear why 276 
our results differ from those of Arai et al. (2011) as the variation in anticoagulant 277 
therapy (with the exception of one dog) is minor and would have been more likely to 278 
reduce coagulation related problems.  The group at Colorado State have published 279 
several reports on the use of warfarin in dogs, (Arai et al. 2011, Monnet & Morgan 280 
2005, Orton et al. 2005), so we conclude that some of the complications we saw 281 
associated with anticoagulation were due to our relative inexperience, but also that 282 
this remains problematic even in the hands of those more experienced in its use.  283 
Two dogs in the study reported here died of septic complications, one dog four days 284 
after surgery and the other dog ten days after surgery.  Both of these dogs had 285 
recovered uneventfully initially, having received cefuroxime (Zinacef; 286 
GlaxoSmithKline), during the perioperative period.  In both dogs, multi resistant 287 
enterobacteriaciae were involved in the infection.  It is assumed, therefore, that these 288 
were nosocomial infections that gained access to the body through either the 289 
intravenous access sites, chest drain or urinary catheter.  Whilst we endeavored not to 290 
leave such catheters in longer than necessary, the critical nature of the first 24 -48 291 
hours recovery period necessitates intensive monitoring and such “instrumentation” is 292 
essential.  Clearly, in any busy hospital, it is advisable to remove any instrumentation 293 
as soon as it is reasonable to do so, to eliminate or reduce the risk of ascending 294 
infection.  Imipenem was used in the case subsequently to these two cases for 48 295 
hours, based on the above dogs’ culture and sensitivity and the presumption that these 296 
were hospital acquired. We have subsequently reverted back to the protocol of using 297 
cefuroxime and now de-instrument dogs sooner if they are stable.  298 
The reasons for the poorer outcome in the study reported here remain unclear.   With 299 
so many variables (surgery team, anaesthesia team, cross clamp time, bypass time, 300 
total surgery time, valve type used, weight, etc) that could affect outcome, a larger 301 
number of dogs undergoing this procedure would have to be studied. Based on the 302 
results reported here, we have to conclude that at least in our hands, bioprosthetic 303 
tricuspid valve replacement in dogs has poor results with a high short term mortality 304 
rate and a short survival time postoperatively.  305 
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  350 
Table 1: Signalment and survival details 351 
Case Breed 
Age at surgery 
(months) 





61 52 246 
2 Rottweiler 7 19·5 5 
3 Labrador retriever 12 25 370 
4 Bassett hound 36 18·5 240 
5 Labrador retriever 13 28 1277 
6 Golden retriever 10 23 1 
7 Labrador retriever 36 34 14 
8 Dogue de 
Bordeaux 
13 59 4 
9 Golden retriever 13 30 ? 
 352 
  353 
Figure 1: Sutures of 2-0 TiCron placed in the tricuspid annulus with pledgets on the 354 
ventricular side 355 
 356 
Figure 2: Prosthetic valve mounted on handle, after preplaced sutures have been 357 
passed through suturing ring 358 
 359 
 360 
Figure 3: Post-mortem picture of thrombus on valve (day four postoperatively, case 8) 361 
 362 
